BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview
ZyVersa Therapeutics Inc - Units (1 Ord Share Class A & 3/4 War)

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Return on Equity

Latest ROE for ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War): 173.38% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

173.38%

Return on Equity

173.38%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

The latest ROE for LSPRU is 173.38%. That is above the sector sector average of -5.72%. Investors often review this figure alongside ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, LSPRU currently prints 173.38% for ROE, while the sector average sits near -5.72%. That is roughly 3129.9% above the sector mean. Large gaps often invite a closer look at ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s growth, margins, and balance sheet.

Return on Equity shows how effectively ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) converts resources into returns. At 173.38%, LSPRU may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LSPRU's ROE (173.38%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.